Erythropoietin, the hormone that is the primary regulator of erythrocyte production, has been purified from anemic-sheep plasma, with a purification factor of more than 1 million. Gel electrophoresis shows that the major contaminant is desialated erythropoietin.
Erythropoietin is the primary inducer of erythrocyte formation in vertebrates (1) . As such, it is important both for the study of the molecular mechanisms involved in cell differentiation, and for possible therapeutic use in some types of refractory human anemias. The purification of erythropoietin, until now, had not progressed to the stage where its chemical and physical properties could be studied directly. Nor could preparations be considered suitably pure for administration to patients. We are now reporting on the purification of erythropoietin derived from anemic-sheep plasma to a state almost free of impurities.
Details of bioassay and of the first steps in the fractionation of sheep plasma have already been published (2-4). The starting material used in the work described in this preliminary communication was an ammonium sulfate fraction (Step IV) prepared as described earlier (4) and generously supplied to us by Dr. L. 0. Jacobson. It was dissolved in 3 M LiCl(5) and the fraction that precipitated between alcohol concentrations of 65 and 90% (fraction P7) was collected. This fraction was desalted and chromatographed on sulfoethyl-Sephadex. The fractions that were eluted with acetate buffers at the following concentrations were collected and pooled: 0.015 M, pH 5.0, 0.0175 M, pH 5.28, and 0.20 M, pH 5.6 (fractions SE 4, 5, 6) . This pooled fraction was desalted, and further purified by adsorption on, and elution from, calcium phosphate gel (6) .
The components that were eluted with 5 X 10-4 M phosphate buffer at pH 7.3 were collected (CaP eluate fraction) and chromatographed on a methylated albumin-Kieselguhr Gel electrophoresis of erythropoietin. Gels, which were 3 cm long and 0.2 cm in diameter, were prepared with 7.5% acrylamide and 0.2% methylene-bisacrylamide. After 90 min at 100 V, the gels were removed from the tubes and cut into 32 slices, which were counted in a crystal scintillation counter. The open circles in the top two frames show the total counts in the slice; the closed circles show the counts after fixing in 20% sulfosalicylic acid and washing. The bottom curve shows the biological activity recovered from slices of polyacrylamide gel. The total activity recovered from the polyacrylamide gel was greater than 80%.
expected from the known amount of protein put on the gel. A less-pure preparation (6500 units/mg of protein) that had been iodinated with ""I by Dr. P. M. Cotes of Mill Hill, London, was examined by the same electrophoretic method; we found that more than 95% of the labeled protein was lost in the fixation process. None of the alternative fixation processes that we tried yielded results that could be used for a test of heterogeneity, so we were forced to use the labeling method.
For studies of homogeneity we used a MAK-column fraction similar to MAK4, but derived from a larger experiment. This preparation (MAK-7) had a potency of 8500 units/mg of protein when repeatedly assayed by the fasted-rat method (2) and by the polycythemic-mouse method (3). When MAK-7 was assayed in rat bone-marrow cultures (unpublished results) over the range of 0.004-0.400 units/ml, there was no evidence of inhibition of either iron uptake or of hemoglobin synthesis, and the plot of log dose versus log response was linear except at the highest level. The MAK-7 material was labeled with carrier-free 125I (9) and, after removal of the greater part of the nonprotein label by gel filtration, the labeled erythropoietin was lyophilized and dissolved in a small amount of water. It was analyzed by micro gel electrophoresis, with the results shown in Fig. 1 . After the run was over, the gel was cut into 32 slices of 0.91-mm thick; each slice was counted. The single major peak, with a relative mobility of 0.52, has a small but definite shoulder on its slower side that contains about 7.5% of the total radioactivity. There are also two minor peaks that run faster than the major one (less than 5% of the total) and a small amount of label at the origin, which is probably denatured protein. The labeled MAK-7 fraction was desialated by using a purified neuraminidase from Cholera vibrio, kindly supplied by Dr. S. Roseman, and examined on a similar gel. The desialated erythropoietin had a relative mobility of 0.35 and the shoulder was no longer evident. We suggest that the shoulder was due to the presence of a small amount of partially or completely desialated erythropoietin. Fig. 1 also shows (closed circles) that the loss of labeled erythropoietin by fixation of the gel slices with sulfosalicylic acid is very much less when the hormone has been desialated.
Since desialation results in complete loss of activity when erythropoietin is assayed by the in vivo methods, we can infer that the active material in the MAK-7 preparation has a potency of 9200 units/mg of protein.
A less highly purified erythropoietin preparation was run on a gel that was sliced as described above. The erythropoietin activity was then eluted from the gel slices and assayed in vitro (unpublished results). The active material had a relative mobility of 0.54, and a small amount of activity at the position of the desialated erythropoietin. These data indicate that the MAK-7 peak was, in fact, erythropoietin and that the major contaminant was desialated erythropoietin.
It is clear from the very low yield that we will have to find much improved methods of purification before we will be able to accumulate enough pure erythropoietin for detailed study of its chemical structure and before we can make tests of its clinical efficacy.
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